This indicates that TRIM44 could serve as a valuable prognostic marker for aggressive MM with translocations, implicating TRIM44 expression in the pathogenesis and progression of MM and potentially influencing treatment outcomes. Here, TRIM44 is linked to Miyoshi myopathy.